share_log

China Meheco Group (SHSE:600056) Takes On Some Risk With Its Use Of Debt

China Meheco Group (SHSE:600056) Takes On Some Risk With Its Use Of Debt

中国医药集团(上证: 600056)在使用债务方面存在一定风险
Simply Wall St ·  08/03 20:06

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that China Meheco Group Co., Ltd. (SHSE:600056) does use debt in its business. But the more important question is: how much risk is that debt creating?

戴维·伊本(David Iben)的这句话说得好:“波动性不是我们关心的风险。我们关心的是避免资本的永久损失。” 当我们考虑一家公司的风险有多大时,我们总是喜欢看它使用债务的情况,因为债务过载可能会导致毁灭。我们可以看到,中国医药集团股份有限公司(SHSE:600056)的确在其业务中使用了债务。但更重要的问题是:这些债务创造了多少风险?

When Is Debt A Problem?

什么时候负债才是一个问题?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we think about a company's use of debt, we first look at cash and debt together.

债务是帮助企业增长的工具,但如果企业无法偿还债权人,那么它就存在于债权人的摆布之下。最终,如果公司无法实现偿还债务的法律义务,股东可能会一无所有。然而,更常见(但仍然昂贵)的情况是公司必须以廉价的股票价格稀释股东,只是为了控制债务。当然,许多公司使用债务来资助增长,没有任何负面影响。当我们考虑企业使用债务的情况时,我们首先会考虑现金和债务的总量。

What Is China Meheco Group's Debt?

中国医药集团的债务是什么?

The chart below, which you can click on for greater detail, shows that China Meheco Group had CN¥5.50b in debt in March 2024; about the same as the year before. However, it does have CN¥2.63b in cash offsetting this, leading to net debt of about CN¥2.87b.

下面的图表(单击可获得更多详细信息)显示,中国医药集团于2024年3月的债务为55亿元人民币,与去年大致相同。然而,它确实有26.3亿元人民币的现金抵消这笔债务,导致净债务约为28.7亿元人民币。

big
SHSE:600056 Debt to Equity History August 4th 2024
SHSE:600056权益为债务历史记录的图表,截至2024年8月4日。

A Look At China Meheco Group's Liabilities

看一下中国医药集团的负债情况

According to the last reported balance sheet, China Meheco Group had liabilities of CN¥18.5b due within 12 months, and liabilities of CN¥4.81b due beyond 12 months. Offsetting this, it had CN¥2.63b in cash and CN¥17.9b in receivables that were due within 12 months. So its liabilities outweigh the sum of its cash and (near-term) receivables by CN¥2.79b.

根据最近公布的资产负债表,中国医药集团截至12个月内到期的负债为185亿元人民币,超过12个月到期的负债为48.1亿元人民币。抵消这一点的是,它拥有26.3亿元人民币的现金和179亿元人民币的应收账款,这些账款在12个月内到期。因此,其负债超过其现金和(短期)应收账款总和279亿元人民币。由于中国医药集团公开交易的股票总价值为156亿元人民币,因此这种负债水平似乎不太可能构成重大威胁。尽管如此,显然,我们应该继续监控其资产负债表,以免情况变得更糟。

Since publicly traded China Meheco Group shares are worth a total of CN¥15.6b, it seems unlikely that this level of liabilities would be a major threat. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse.

中国医药集团的债务与息税折旧及摊销前利润之比(债务/EBITDA)为1.9,巧妙而负责地使用债务。而且它拥有相当有吸引力的利息保障(EBIt为7.2倍的利息支出),这确实没有消除这种印象。不幸的是,中国医药集团的EBIt在过去四个季度中下降了19%。如果收益率继续以这个速度下降,那么处理债务将比带着三个5岁以下的孩子去一家花哨的餐厅容易得多。在分析债务水平时,资产负债表是显然的起点。但是,您不能孤立地看待债务;因为中国医药集团将需要盈利来偿还债务。因此,在考虑债务时,绝对有必要看一下收益趋势。点击此处以获取交互式快照。

We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). Thus we consider debt relative to earnings both with and without depreciation and amortization expenses.

通过查看公司的净债务与利息、税、折旧、摊销前利润(EBITDA)之比以及它的利息费用(利息覆盖率)可以衡量一个公司的债务负担与收益能力。因此,我们考虑将债务与有无计算折旧和摊销费用的收益相对比。

With a debt to EBITDA ratio of 1.9, China Meheco Group uses debt artfully but responsibly. And the alluring interest cover (EBIT of 7.2 times interest expense) certainly does not do anything to dispel this impression. Unfortunately, China Meheco Group's EBIT flopped 19% over the last four quarters. If earnings continue to decline at that rate then handling the debt will be more difficult than taking three children under 5 to a fancy pants restaurant. When analysing debt levels, the balance sheet is the obvious place to start. But you can't view debt in total isolation; since China Meheco Group will need earnings to service that debt. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

最后,企业需要自由现金流来偿还债务;会计利润根本不能胜任。因此,我们明确需要查看EBIt是否导致相应的自由现金流。在过去三年中,中国医药集团的自由现金流相当于其EBIt的28%,低于我们的预期。这种较弱的现金转换使处理负债更加困难。

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. So we clearly need to look at whether that EBIT is leading to corresponding free cash flow. In the last three years, China Meheco Group's free cash flow amounted to 28% of its EBIT, less than we'd expect. That weak cash conversion makes it more difficult to handle indebtedness.

中国医药集团的EBIt增长率在这种分析中确实是一个真正的负面因素,尽管我们考虑的其他因素都使它看起来更好。但是好的一面是,它用EBIt覆盖利息支出的能力也不错。我们还应该注意,与中国医药集团类似的医疗保健行业公司通常会毫无问题地使用债务。当我们考虑所有讨论的因素时,我们认为中国医药集团在使用债务方面存在一些风险。因此,虽然这种杠杆率确实增加了股权回报率,但我们并不希望看到它从这里开始增加。毫无疑问,我们从资产负债表上了解债务的大部分。但是,并非所有投资风险都驻留在资产负债表上——远非如此。我们已确定与中国医药集团有3个警告信号(至少有1个让我们不太满意),了解它们应该是您投资过程的一部分。

Our View

我们的观点

China Meheco Group's EBIT growth rate was a real negative on this analysis, although the other factors we considered cast it in a significantly better light. But on the bright side, its ability to to cover its interest expense with its EBIT isn't too shabby at all. We should also note that Healthcare industry companies like China Meheco Group commonly do use debt without problems. When we consider all the factors discussed, it seems to us that China Meheco Group is taking some risks with its use of debt. So while that leverage does boost returns on equity, we wouldn't really want to see it increase from here. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. We've identified 3 warning signs with China Meheco Group (at least 1 which doesn't sit too well with us) , and understanding them should be part of your investment process.

当然有一些行业使用债务不会有问题,医疗保健行业正是其中之一。对于其他行业,下降率也有所鼓舞。当我们考虑所有因素时,我们认为中国医药集团在使用债务方面存在一些风险。虽然这种杠杆化确实提高了股权回报率(ROE),但我们不希望它进一步增加。我们需要看到公司产生一些实际的自由现金流以用于偿还债务,而不仅仅是会计利润。 这篇文章列出的数据和意见都是根据公司近期的情况得出的。 我们对数据的准确性没有任何保证。行业应被翻译为行业板块,学习应被翻译为课堂,业务应被翻译为业务,看跌应被翻译为put,基金应被翻译为基金,分享应被翻译为分享,can应被翻译为可以,中国医药集团应被翻译为中国医药,开始控件应被翻译为开始,自由现金流应被翻译为自由现金流,其他应被翻译为其他,所有板块应被翻译为所有板块。

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

如果您有兴趣投资能够在不负债的情况下增长利润的企业,请查看这份免费列表,其中列出了在资产负债表上拥有净现金的成长型企业。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发